Global Migraine Market Driven by Growing Number of Smokers

Published Date : Jun 19, 2017

ALBANY, New York, June 19, 2017 - has added a new research report to its expansive database on the global pharmaceutical industry and its players. The new report, titled “Global Migraine Market: Industry Analysis & Outlook (2017-2021),” is a comprehensive reports of the factors that are augmenting or hindering the growth rate of the market. The report also suggests areas where players in the market may find greater opportunities for the coming years, and the overall shape of the market within the given forecast period from 2017 to 2021. The report also includes a regional perspective of the global migraine market, allowing players to compartmentalize their expansion strategies and implement them with a greater chance of success.

According to the report, one of the key factors driving the global migraine market and the overall demand for migraine medication is the growing number of smokers across the world. The increasing number of people picking up smoking is directly linked to factors such as a growing urban population, increasingly stressful lives, and growing disposable income. Research has conclusively linked the chances a person can be inflicted by migraines to whether they smoke or not.

Along with the growing number of smokers, the global migraine market is also being propelled by the growing population of women in the world. Social progress has stabilized the overall ratio of male to female birth rates, thereby increasing the female demographic across the world. Medical research has shown that women are far more prone to being inflicted by migraines than men, thereby creating a direct impact on the demand for migraine medication across the world.

For Sample Copy, click here:

Other factors of growth affecting the global migraine market include the growing awareness of migraine types and their treatments, along with the increasing availability of these treatment options in more regions. Emerging economies are especially locations of high interest to all globally prominent players in the global migraine market, as the increasing expenditure of these regions on the healthcare and pharmaceutical industries is allowing a greater scope of market penetration for them. The growing healthcare outreach has allowed for more detailed studies on headache disorders and migraines to be possible, thereby allowing the market to accelerate its rate of development of safe and effective medications and other treatments.

The global migraine market, however, is currently restrained by factors such as the limitations faced by migraine therapies, the increasingly stringent regulatory policies regarding the use of several drugs and treatments, and the overall high cost of certain effective treatments.

The research report includes a thorough reports of the competitive landscape of the global migraine market. This reports incorporates the activities and profiles of the four leading players in the market: Alder Biopharmaceuticals, Teva Pharmaceuticals, Eli Lily and Company, and Amgen, Inc. The report provides updated information on these prominent players based on their business and financial overviews, and their overall market strategies.

To order report Call Toll Free: 866-997-4948 or send an email on